Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study

Stanford University

Summary

This study aims to assess the feasibility of performing neuropsychological testing to measure the cognitive performance of individuals following Axicabtagene ciloleucel CAR-T therapy at Stanford.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * \>/= 18 years-old * Treated with Axicabtagene ciloleucel CAR-T therapy at Stanford Or * Treated with standard commercial Axicabtagene ciloleucel CAR-T therapy elsewhere and followed primarily by SHC Blood and Bone Marrow transplant providers * \>/= 6 months from the date of CAR-T infusion * Fluent in English * Able to attend and participate in in-person testing (Arm I) * Able to participate in remote video testing with adequate workspace, computer and internet capabilities for a reliable telehealth video connection (Arm II) Exclusion Criteria: * Concurrent enrollment i…

Interventions

Behavioral
Neuropsychological testing
Upon completion of the consent, the subject will be booked into an available 90 minute in-person or remote neuropsychological testing

Location

Stanford Cancer Center
San Francisco, California
bjscott@stanford.edu bjscott@stanford.edu

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford - A Pilot Study

Summary

Eligibility

Interventions

Location

Run this study?

Details

Conditions